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F.vanLeeuwen@maastrichtuniversity.nl (F.W. van LeeMutant ubiquitin (UBB+1) accumulates in the hallmarks of tauopathies and polyglutamine diseases.
We show that the deubiquitinating enzyme YUH1 of Saccharomyces cerevisiae and its mouse and
human ortholog UCH-L3 are able to hydrolyze the C-terminal extension of UBB+1. This yields another
dysfunctional ubiquitin molecule (UBG76Y) with biochemical properties similar to full length UBB+1.
UBB+1 may be detected in post-mortem tissue due to impaired C-terminal truncation of UBB+1.
Although the level of UCH-L3 protein in several neurodegenerative diseases is unchanged, we show
that in vitro oxidation of recombinant UCH-L3 impairs its deubiquitinating activity. We postulate
that impaired UCH-L3 function may contribute to the accumulation of full length UBB+1 in various
pathologies.
Crown Copyright  2011 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
Ubiquitin is essential for cellular homeostasis. Polyubiquitin
chains are conjugated to proteins designated for proteasomal
degradation by an ubiquitin activating enzyme (E1), a ubiquitin
conjugating enzyme (E2), and a ubiquitin ligase (E3) [1]. For poly-
ubiquitination, the C-terminal glycine of one ubiquitin molecule is
conjugated to one of the internal lysines of another ubiquitin mol-
ecule [1].
Ubiquitination is counterbalanced in humans by nearly 100
deubiquitinating enzymes (DUBs) which are essential for (re)gen-
eration of ubiquitin [2] and controlling epigenetic mechanisms
by deubiquitinating histones [2,3]. DUBs can, for example, protect
proteins from degradation by deubiquitination [4] but also assist in
proteasomal degradation through deubiquitination of substrates
after binding to the proteasome [5]. One subfamily of DUBs is
the group of ubiquitin C-terminal hydrolases (UCHs). UCHs are able
to hydrolyze ubiquitin precursor proteins and to remove small ad-
ducts from ubiquitin in vitro [6]. At least one enzyme belonging to
this family, UCH-L1, is genetically linked to neurodegenerative dis-
orders [7,8].
In many neurodegenerative disorders aberrant proteins aggre-
gate and accumulate in inclusions which often contain ubiquitind by Elsevier B.V. on behalf of Fede
rsity.nl (F.J.A. Dennissen),
uwen).[9,10]. Moreover, impaired proteasome function, mutated ubiqui-
tin hydrolases and speciﬁc ubiquitin ligases have been implicated
in neurodegenerative disorders [7,11–13]. This suggests that dys-
function of the ubiquitin–proteasome system (UPS) may play a role
in these diseases.
In Alzheimer’s disease (AD) and other tauopathies as well as
polyglutaminopathies, a mutant ubiquitin (UBB+1), which is en-
coded by an erroneously transcript [14], colocalizes with the
hallmarks (e.g., neuroﬁbrillary tangles and neuritic plaques) asso-
ciated with these pathologies [14,15] while it was undetectable
in brains of young controls and in synucleinopathies. UBB+1 mRNA
was found in all brains tested [16] which suggests that healthy
individuals are able to process UBB+1 while UBB+1 accumulates in
affected brains. UBB+1 mRNA codes for a ubiquitin molecule with
a C-terminal glycine to tyrosine substitution and an addition of
19 amino acids. Consequently, UBB+1 cannot be used for
(poly)ubiquitination. UBB+1 impairs the UPS when ubiquitinated
and ubiquitinated UBB+1 is refractory to disassembly by DUBs
[17–19].
Although UBB+1 is targeted for proteasomal degradation [16],
recent advances indicate that UBB+1 does not meet the prerequi-
sites for efﬁcient proteasomal degradation. Recent studies revealed
that the C-terminal extension of UBB+1 is too short for efﬁcient pro-
teasomal degradation [20,21]. In the present study, we show that
the UCH-L3 is able to cleave the C-terminus of UBB+1. In addition,
oxidation of UCH-L3 impairs its hydrolysis activity. We therefore
propose that accumulation of UBB+1 may, in part, be due toration of European Biochemical society. All rights reserved.
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suggest that impaired truncation is caused by inactivation of UCH-
L3 in the oxidative environment that has been shown to be associ-
ated with various neurodegenerative disorders [22].
2. Materials and methods
2.1. Plasmids
The generation of plasmids for pCMV-mycUBB+1, pCMV-my-
cUBG76V, pCMV-mycUBB+1 K0 and pYES2-mycUBB+1 was described
previously [21]. For cloning of the UCHs, mRNA from HEK293 cells
or hippocampus from human and mouse was isolated with stan-
dard Trizol–chloroform extraction methods after which cDNA
was generated using the ﬁrst strand synthesis kit (Fermentas).
The cDNA for the UCHs was PCR ampliﬁed and cloned into a
pEF5-HA vector [23] (Supplementary Table 1). Human UCH-L3
was subcloned into pET28a according to a standard protocol.
Cloned DNA fragments were sequenced (GATC-Biotech) to control
for mutations. For transfection of cells all plasmids were ampliﬁed
and isolated with maxiprep kit (Qiagen).
2.2. Antibodies
All the antibodies and antibody dilutions can be found in Sup-
plementary Table 2.
2.3. Yeast strains, growth and transformation of the yeast miniscreen
The miniscreen was generated by selecting 175 deletion strains
(Supplementary Fig. 1 and Supplementary Table 3) from the gen-
ome wide deletion collection (BY4741 MATa his3D1 leu2D0
met15D0 ura3D0 background, kind gift from Dr. F. van Leeuwen,
NKI, Amsterdam) on YPD-agar (1% bacto-yeast extract, 2% bacto-
peptone, 2% dextrose, 2% agar) plates in a 96-well format. Selection
criteria were that the gene was involved in protein quality control
and/or protein/peptide degradation (Table 1).
Yeast transformation was performed according to a modiﬁed
version of a method described for microtiter plate transformation
using the LiAc/SS carrier DNA/PEG [24] (Supplementary Fig. 1).
All transformed yeast strains were grown to a density with an
A600  1.0, collected and dissolved in 17% trichloroacetic acid
(TCA) to isolate their proteins.
2.4. SDS–PAGE and immunoblotting
The precipitated protein pellets fromyeast aswell as the pelleted
mammalian cells were dissolved in 200 ll of loading buffer contain-
ing 130 mM Tris–HCl, pH 8.0, 10% (v/v) Glycerol, 2.3% (w/v) SDS,
1% DTT and 0.1% bromephenolblue and resolved by SDS–PAGE on
12% Bis-Tris Gels (NuPAGE Novex, Invitrogen) or 16% Tris-
Tricine gel, transferred to nitrocellulose membranes (pore size
0.2 lm, Invitrogen) and immunostained according to standardTable 1
The number of genes per category used for the miniscreen.
Categories Number of genes




Neddylation and sumoylation 8
Deubiquitinases 16
Peptidases/metalloproteases 55
Miscellaneous 2protocol [25]. Proteins were visualized by an enhanced chemilumi-
nescence (ECL™, Amersham) or with the Odyssey scanner (LI-
COR). When using a HRP-conjugated labeled secondary antibody,
loading control (b-actin) was stained consecutively after detection
of the protein of interest. For the IRDye labeled secondary antibod-
ies, two differently labeled antibodieswere usedwhich could be de-
tected independently by multi-ﬂuorescence scanning of the
Odyssey system (LI-COR). The UCH-L3 protein of AD and control
patients were immunoblotted according to the standard Odyssey
manufacturing protocol and double stained for UCH-L3 and GAPDH
for loading control.
2.5. Mammalian cell culture and transfection
HEK293 and HeLa cells stably transfected with a reporter for the
ubiquitin fusion degradation (UFD) pathway (HeLa UBG76V-GFP)
[26] were cultured in Dulbecco’s modiﬁed Eagle’s medium (Gibco)
supplemented with 10% of fetal calf serum (BODINCO), 50 units/ml
of penicillin (Gibco) and 50 units/ml of streptomycin (Gibco). For
transfections, 2 lg of plasmid DNA and 6 lg of Polyethylenamine
‘‘Max’’ (Polysciences) were mixed in 50 ll PBS. Solutions were
incubated at room temperature for 15 min and subsequently
added to cells in 1 ml of serum and antibiotic free Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) (Gibco). The culture medium was
changed 4–5 h after transfection to fresh-serum-supplemented
DMEM.
2.6. Mass spectrometry (MS) of truncated UBB+1
HEK293 cells were transiently transfected with pEF5HA-
UCH-L3; 24 h later cells were harvested and lysed in lysis buffer
containing 50 mM Tris–HCl (pH 7.6), 50 mM NaCl and 5 mM DTT.
Ten micrograms of recombinant HISUBB+1 was added to 50 ll of
the lysate (50 mg/ml total protein) and incubated overnight at
37 C. HISUBB+1 and truncated HISUBB+1 were puriﬁed by using
TALON™ Immobilized Metal Afﬁnity Chromatography (IMAC)
Resin (BD-Biosciences) according to the manufacturer’s recom-
mendation. Samples were resolved by SDS–PAGE gel electrophore-
sis after which the bands corresponding to full-length and
truncated UBB+1 were cut and digested according to the method
of Shevchenko et al. [27]. The mass spectrometric (MS) analysis
was carried out using a MALDI-TOF/TOF instrument (4800 Proteo-
mics Analyzer, Applied Biosystems) with reﬂector positive ion
mode. For MS analysis, 800–3000m/z mass range was used with
1250 shots per spectrum. A maximum of 20 precursors per spot
with minimum signal/noise ratio of 50 were selected for data-
dependent MS/MS analysis. A 1-kV collision energy was used for
CID, and 2500 acquisitions were accumulated for each MS/MS
spectrum.
2.7. The effect of UBB+1 truncation by UCH-L3 on UFD-pathway
inhibition
HeLa UBG76V-GFP reporter cells were seeded on coverslips. The
cells were transiently transfected with mycUBB+1 or mycUB+1 24 h
post-seeding. The cells were ﬁxed 24 h post-transfection and
stained for the myc tag. The slides were analyzed using a IX81
motorized inverted microscope (Olympus).
2.8. Turnover of full length UBB+1, truncated UBB+1 (UBG76Y) and
UBG76V + 25 in vitro
HEK293 cells were transiently transfected with mycUBB+1,
mycUBBG76Y or UBG76V + 25. Cells were transfected with UBG76V + 25
for turnover control since this extended dysfunctional ubiquitin is
degraded by the proteasome [21]. Turnover was determined 24 h
Table 2
Homology between S. cerevisiae YUH1 and human UCH family members.
Score E-value Positives (%) Identity (%)
UCH-L3 286 3.0E25 51 32
UCH-L1 206 6.0E16 51 30
UCH-L5 134 1.0E7 43 27
BAP1 88 3.1E2 41 25
Table 3
Fig. 1. Yeast ubiquitin hydrolase 1 (YUH1) is responsible for C-terminal truncation
of human UBB+1 in S. cerevisiae. Western blot of a section of the miniscreen. The
Dyuh1 deletion strain cannot truncate mycUBB+1 (lane 6). Ectopic expression of
recombinant YUH1 restores truncation of mycUBB+1 in the Dyuh1 strain (lane 7).
2570 F.J.A. Dennissen et al. / FEBS Letters 585 (2011) 2568–2574post-transfection by adding cycloheximide to the medium with a
ﬁnal concentration 50 lg/ml. Cells were harvested for Western
blot analysis at 0, 1, 2, 4, 6 and 8 h after blocking translation. Cells
were also treated with proteasome inhibitor Bortezomib (10 nM)
to determine the effect of inhibition of the proteasome on steady
state levels of the UBx species. Membranes were probed with
anti-myc and anti-GAPDH antibodies for loading control.
2.9. Production of recombinant HISUCH-L3, HISUBB+1 and generation of
the +1 peptide
Recombinant HISUCH-L3 and HISUBB+1 were generated according
to a standard protocol. Rosetta™ bacteria were transformed with
pET28a-HISUCH-L3 or pET28a-HISUBB+1 and grown overnight in
selective medium (25 lg/ml of kanamycin) at 37 C. Overnight cul-
tures were diluted into 5 ml selective medium to OD600 = 0.1 and
incubated at 37 C. After growing to OD600 = 0.8 isopropyl beta-D-
thiogalactoside (IPTG) was added to a ﬁnal concentration of
1 mM. Bacteria were incubated at 37 C with IPTG for 4 h, pelleted
and frozen until further processing. HISUCH-L3 and HISUBB+1 were
puriﬁed using BD TALON™ Metal Afﬁnity Resin according to the
manufacturer’s protocol. One microgram of HISUCH-L3 and 5 lg
of HISUBB+1 were mixed in 50 ll of lysis buffer (see Section 2.6)
and incubated overnight at 37 C. Loading buffer was added and
proteins were resolved by SDS–PAGE (see Section 2.4). HISUBB+1
was stained with Coomassie or immunoblotted with anti-HIS and
UBI-3 antibodies.
2.10. The effect of oxidation on UCH-L3 activity
Recombinant HISUCH-L3 was incubated in 25 mM HEPES buffer
(pH 7.2) or in 25 mM HEPES buffer (pH 7.2) containing 25 mM
ascorbate and 100 lM FeCl3 for 5 h at 37 C. Analysis of normal,
oxidized or inhibited UCH-L3 activity was done by co-incubating
with HISUBB+1 as has been described (see Section 2.9). UCH-L3
was inhibited by adding UCH-L3 inhibitor (4,5,6,7-Tetrachloroin-
dan-1,3-dione, Calbiochem) to the mix at a ﬁnal concentration of
10 lM.
2.11. UCH-L3 quantiﬁcation in post-mortem tissue from AD, PD, HD
and control patients
Fresh frozen hippocampus tissue of AD and control brains, fresh
frozen cingulate gyrus (BA24) of PD and control brains and fresh
frozen prefrontal cortex of HD and control brains (Supplementary
Table 4) were homogenized in lysis buffer containing 50 mM Tris–
HCl (pH 7.6) and 50 mM NaCl at 4 C. Total protein concentration
was determined with the Bio-Rad protein assay. After SDS–PAGE
and transfer, the membrane was immunoblotted with anti-UCH-
L3 and anti-GAPDH antibodies. Quantiﬁcation was performed with
the LI-COR analysis software after multi-ﬂuorescence scanning of
the membrane [28].
2.12. Statistical analysis
The difference in UCH-L3 quantity has been tested with a 2-
sided distribution free Mann–Whitney test (accepted level of sig-
niﬁcance P < 0.05).Homology between mouse and human UCH family members.
Score E-value Positives (%) Identity (%)
UCH-L1 1119 1.0E122 99 95
UCH-L3 1188 1.0E130 100 98
UCH-L4a 1145 1.0E125 97 94
UCH-L5 1653 0.0 99 96
BAP1 3500 0.0 95 93
a UCH-L4 is aligned with human UCH-L3.3. Results and discussion
3.1. Loss of YUH1 gene abolishes the C-terminal truncation of UBB+1
To study post-translational processing of myc-tagged UBB+1
(mycUBB+1) in vivo, Saccharomyces cerevisiae (baker’s yeast) wasused as a model organism. A selection of 175 yeast deletion strains
from a genome-wide deletion library was made to assemble the
miniscreen (Supplementary Table 1).
In the yeast strains, we detected in addition to UBB+1 a trun-
cated product of UBB+1 (size  11 kDa) that corresponds to the size
of myc-tagged ubiquitin (Fig. 1B, lanes 2–6). We observed the trun-
cated product in all tested deletion strains except for the Dyuh1
strain which is lacking the yeast ubiquitin hydrolase 1 gene (lane
6). Processing of mycUBB+1 could be rescued in the Dyuh1 strain
by ectopic expression of YUH1 conﬁrming that this enzyme is re-
quired for processing of mycUBB+1 (lane 7).
3.2. Human and mouse UCH-L3 are able to hydrolyze the UBB+1 C-
terminus and generate truncated UBB+1 (UBG76Y)
YUH1 is member of the ubiquitin carboxy-terminal hydrolase
(UCH) family. In humans this family consist of: UCH-L1, UCH-L3,
UCH-L5 and BAP-1 of which UCH-L3 shows the highest homology
with YUH1 (Table 2). Mice express UCH-L4, a close homolog of
UCH-L3, in addition to the human enzymes (Table 3). We cloned
cDNAs coding for UCH-L1, UCH-L3 and UCH-L5 of both mouse
and human and UCH-L4 of mouse into an expression vector. We
also cloned the CRA_f isoform of UCH-L3 from human cDNA, a nat-
urally occurring UCH-L3 isoform missing amino acids 15–18
(VTNQ). These amino acids are part of a putative substrate-binding
site of UCH-L3 and presumably the CRA_f isoform has lost its afﬁn-
ity for ubiquitin [29]. HEK293 cells were transiently co-transfected
with UBB+1 and the respective peptidases (Fig. 2A). Cleavage of
UBB+1 is strikingly increased when co-transfected with UCH-L3
(Fig. 2A, lanes 3 and 7). Transfection with the CRA_f isoform of
UCH-L3 (lane 4), UCH-L4 (lane 8), UCH-L1 (lanes 2 and 6) or
UCH-L5 (lanes 5 and 9) did not result in an increase in truncated
Fig. 2. Human and mouse UCH-L3 are able to truncate human UBB+1 yielding UBG76Y but no intact C-terminal peptide. (A) UBB+1 is a substrate for UCH-L3 from human and
mouse. The asterisk marks the truncated UBB+1 product. (B) Identiﬁcation of the hydrolysis site in UBB+1 by UCH-L3. Two peptides are unique (asterisks) and correspond to
LRGY (panel 1, 508.3⁄) and LRGYADLR (panel 4, 963.6⁄). (C) Truncation of recombinant HISUBB+1 by recombinant HISUCH-L3 (lane 1). Immunostaining with anti-HIS-tag
antibodies in red (lane 2) and immunostaining using antibodies raised against the C-terminal extension of UBB+1 (UBI-3) in green (lane 3). Artiﬁcial peptide corresponding to
the C-terminal extension of UBB+1 is shown as a positive control (lane 5).
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The truncated species observed in the UBB+1 single transfection
control is due to the endogenous C-terminal hydrolyze activity in
HEK293 cells. To determine the hydrolysis site in UBB+1 by UCH-
L3, we incubated recombinant HISUBB+1 with an extract of
HEK293 cells transfected with human HAUCH-L3. Resolving pro-
teins on high resolution SDS–PAGE and subsequent Coomassie
staining yielded two distinct bands corresponding to UBB+1 and
truncated UBB+1. The mass spectrometry data revealed that one
peptide was unique to truncated ubiquitin (LRGY, Fig. 2B, top pan-
els) while full length UBB+1 yielded a different peptide (LRGYADLR,
Fig. 2B, lower panels) This ﬁnding reveals that the truncated spe-
cies was indeed C-terminally truncated UBB+1 with the ﬁnal amino
acid being tyrosine 76 (Y76). Truncation of UBB+1 prevents detec-
tion by antibodies raised against its C-terminus. Both truncated
and full length UBB+1 could be detected by Coomassie staining
(Fig. 2C, lane 1) and by using antibodies against the N-terminal
myc-tag (Fig. 2C, lane 2). Accordingly, the UBI-3 antibody, which
speciﬁcally recognizes the +1 extension, reacted with the full
length UBB+1 while we were unable to detect UBG76Y (Fig. 2C, lane
3). The cleaved +1 peptide could not be detected by Coomassie
staining or by using the UBI-3 antibodies (Fig. 2C, lanes 1 and 3).
Previously, it was shown that the UCH of Drosophila melanogaster
(UCH-D) could not cleave the C-terminal extension of UBB+1 [18].
It was proposed that any residue larger than glycine at position76 would result in a steric clash with Asn88 of YUH1 [30]. Conse-
quently, it was concluded that UBB+1 was unsusceptible to cleav-
age by any UCH enzyme and that the C-terminal double glycine
(G75 and G76) was essential for hydrolysis. Indeed, all known sub-
strates (NEDD8 and ubiquitin) of UCH-L3 possess a C-terminal
double glycine. In the present paper we show that, contradictory
to the literature, UCH-L3 and YUH1 are able to cleave the C-termi-
nal extension of UBB+1 despite the fact that the C-terminal glycine
is substituted with a tyrosine.
3.3. Full length and truncated UBB+1 are slowly degraded in vitro and
inhibit the ubiquitin fusion degradation (UFD)-pathway
UPS function can be studied by expressing a ubiquitin-GFP fu-
sion protein. The UBG76V-GFP reporter substrate is degraded by
the proteasome by a well-mapped functional cascade of proteins
(UFD-pathway). Impairment of one or more proteins involved in
this cascade, including the proteasome, causes accumulation of
UBG76V-GFP. To determine the effect of truncated UBB+1 (UBG76Y)
on the UFD-pathway reporter, UBG76Y was transiently transfected
in HeLa UBG76V-GFP cells. Normally, this reporter is rapidly de-
graded resulting in low steady state levels (Fig. 3A). UBB+1 induced
UFD-impairment (Fig. 3A and B) as shown previously [17]. Impair-
ment also occurred by introduction of truncated UBB+1 (UBG76Y,
Fig. 3A and B). UBB+1 has been reported to be too short to be
Fig. 3. UBx species in UBG76V-GFP reporter cells show impairment of the UFD-pathway for dysfunctional ubiquitin. UBB+1 and UBG76Y impair the UFD-pathway (panels A and
B). Full length UBB+1 and UBG76Y are equally slowly degraded in vitro while UBG76V + 25 is undetectable after 2 h (panel C). Bortezomib increases steady state levels of UBx
species to 125–150% of normal levels. The asterisk marks the truncated UBB+1 species.
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ened by an additional 25 amino acids (UBG76V+25) is, however, efﬁ-
ciently degraded by the proteasome. To determine the degradation
rate of UBG76Y compared to UBB+1 and UBG76V+25 turnover was
assessed by cycloheximide chase analysis and Western blotting.Fig. 4. Levels of UCH-L3 in AD, PD and HD and the effect of oxidation of UCH-L3 on hydro
(panel 3) compared to controls. (B) In vitro oxidized UCH-L3 is unable to hydrolyze the
truncation. Truncated species are marked with .mycUBG76Y and UBB+1 are slowly degraded in HEK293 cells
(Fig. 3C). The half life of these species is approximately 8 h,
whereas UBG76V+25 has a half life of approximately 30 min.
Truncation of UBB+1 generates a new species which could have dif-
ferent properties compared to full length UBB+1. However, bothlysis activity. (A) UCH-L3 levels are unchanged in: AD (panel 1), PD (panel 2) and HD
C-terminal extension of UBB+1 and the catalytic activity of UCH-L3 is essential for
Fig. 5. Hypothesis to explain the selective detection of UBB+1 in post-mortem tissue of neurodegenerative disorders. (A) UBB+1 is generated at a slow rate in humans. (B)
Normally the C-terminal extension of UBB+1 is hydrolyzed by a C-terminal hydrolase (e.g., UCH-L3). (C) With impaired hydrolase activity there is accumulation of UBB+1
giving rise to UBB+1 immunoreactivity in post-mortem tissue.
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similar to UBB+1. Truncated and full length UBB+1 both impair the
UFD-pathway and show equally slow turnover rates. Therefore, it
is not to be expected that (impaired) truncation contributes to
neurodegeneration.
3.4. Levels of UCH-L3 are unchanged in neurodegenerative disorders
but UCH-L3 activity is blocked when oxidized
To determine if UCH-L3 levels are changed in neurodegenera-
tive disorders related to presence of UBB+1, we quantiﬁed UCH-
L3 by Western blotting (Fig. 4A). No statistical signiﬁcant
difference was found between AD patients, PD patients or HD pa-
tients (closed bullets) and their respective controls (open bullets).
Oxidative stress is a known feature of neurodegenerative disor-
ders. Cysteine proteases such as UCH-L3 have been known to be
vulnerable to oxidation [8]. Indeed, truncation of HISUBB+1 by
HISUCH-L3 (Fig. 4B, lane 1) is blocked when HISUCH-L3 is oxidized
(Fig. 4B, lanes 1 and 2). Similar results were obtained by inhibiting
the catalytic activity of UCH-L3 by a selective UCH-L3 inhibitor
(Fig. 4B, lanes 4 and 5). It has been reported that UCH-L1 is upreg-
ulated in AD while at the same time it is damaged by oxidative
modiﬁcation reducing net enzyme activity to 30% of the normal le-
vel [8]. Our in vitro data suggest that its closely related isozyme
UCH-L3 may face a similar fate when exposed to oxidative stress
resulting in accumulation of full length UBB+1 (Fig. 5). We at-
tempted to determine the UCH-L3 enzyme activity in protein ly-
sates of human hippocampi (AD and control tissue). Using
human post-mortem tissue lysates, we could not detect any trun-
cation of UBB+1. We attribute this to the post-mortem delay since
using lysates from mouse brain did yield truncated UBB+1.
AD brains show characteristic features. Intracellular hyperphos-
phorylated tangles, extracellular amyloid beta plaques as well as
UBB+1 can be observed in the diseased brains. The origin of these
species is essential for understanding the etiology of AD and to
see opportunities for a therapeutic strategy. Here, we show that
truncated UBB+1 cannot be visualized by antibodies used to detect
UBB+1 in post-mortem tissue. This suggests a new explanation as towhy UBB+1 is detectable in selective neurodegenerative diseases
(Fig. 5). Normally, UBB+1 would be truncated by a C-terminal
hydrolase (e.g., UCH-L3). Truncation could be impaired in neurode-
generative diseases leading to accumulation of full length UBB+1.
According to this hypothesis full length UBB+1 could be regarded
as a marker for dysfunctional UCH-L3 enzyme. Truncation of
UBB+1 can be impaired in neurodegenerative disorders due to oxi-
dation of UCH-L3. Further studies need to be performed to deter-
mine the exact aberration which results in detectable UBB+1
in vivo and its role neurodegenerative disorders.
Acknowledgements
We thank R. van der Schors, Ing. (Free University of Amsterdam,
The Netherlands) for providing the mass spectrometry results and
Prof. Dr. D.A. Hopkins for correcting the English text. We would
also like to thank Drs. R.A.I. de Vos (Laboratory for Pathology,
Enschede, The Netherlands), Prof. Dr. R.A.C. Roos and the Nether-
lands Brain Bank (coordinator Dr. R.I. Huitinga) for providing the
tissue from Alzheimer’s Parkinson’s and Huntington’s disease pa-
tients with matching control tissue.
This research was supported by the Foundation ‘‘De Drie Lich-
ten’’, the International Foundation for Alzheimer Research (ISAO
#06502 and #09514), the International Parkinson Foundation
(2008), the Brain Foundation of the Netherlands (#15F07(2).48
and #2008(1).17) and the Van Leersum Foundation KNAW (2008).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2011.06.037.
References
[1] Hershko, A. and Ciechanover, A. (1998) The ubiquitin system. Annu. Rev.
Biochem. 67, 425–479.
[2] Nijman, S.M., Luna-Vargas, M.P., Velds, A., Brummelkamp, T.R., Dirac, A.M.,
Sixma, T.K. and Bernards, R. (2005) A genomic and functional inventory of
deubiquitinating enzymes. Cell 123, 773–786.
2574 F.J.A. Dennissen et al. / FEBS Letters 585 (2011) 2568–2574[3] Samara, N.L., Datta, A.B., Berndsen, C.E., Zhang, X., Yao, T., Cohen, R.E. and
Wolberger, C. (2010) Structural insights into the assembly and function of the
SAGA deubiquitinating module. Science 328, 1025–1029.
[4] Du, Z. et al. (2010) DNMT1 stability is regulated by proteins coordinating
deubiquitination and acetylation-driven ubiquitination. Sci. Signal. 3, ra80.
[5] Wu, X., Yen, L., Irwin, L., Sweeney, C. and Carraway III, K.L. (2004) Stabilization
of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol.
Cell. Biol. 24, 7748–7757.
[6] Larsen, C.N., Krantz, B.A. and Wilkinson, K.D. (1998) Substrate speciﬁcity of
deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37,
3358–3368.
[7] Leroy, E. et al. (1998) The ubiquitin pathway in Parkinson’s disease. Nature
395, 451–452.
[8] Sultana, R. et al. (2006) Redox proteomics identiﬁcation of oxidized proteins in
Alzheimer’s disease hippocampus and cerebellum: an approach to understand
pathological and biochemical alterations in AD. Neurobiol. Aging 27, 1564–
1576.
[9] Schwartz, A.L. and Ciechanover, A. (2009) Targeting proteins for destruction by
the ubiquitin system: implications for human pathobiology. Annu. Rev.
Pharmacol. Toxicol. 49, 73–96.
[10] Perry, G., Friedman, R., Shaw, G. and Chau, V. (1987) Ubiquitin is detected in
neuroﬁbrillary tangles and senile plaque neurites of Alzheimer disease brains.
Proc. Natl. Acad. Sci. USA 84, 3033–3036.
[11] Keck, S., Nitsch, R., Grune, T. and Ullrich, O. (2003) Proteasome inhibition by
paired helical ﬁlament-tau in brains of patients with Alzheimer’s disease. J.
Neurochem. 85, 115–122.
[12] Kitada, T. et al. (1998) Mutations in the parkin gene cause autosomal recessive
juvenile parkinsonism. Nature 392, 605–608.
[13] Kishino, T., Lalande, M. and Wagstaff, J. (1997) UBE3A/E6-AP mutations cause
Angelman syndrome. Nat. Genet. 15, 70–73.
[14] van Leeuwen, F.W. et al. (1998) Frameshift mutants of beta amyloid precursor
protein and ubiquitin-B in Alzheimer’s and Down patients. Science 279, 242–
247.
[15] van Leeuwen, F.W. et al. (2006) Frameshift proteins in autosomal dominant
forms of Alzheimer disease and other tauopathies. Neurology 66, S86–S92.
[16] Fischer, D.F. et al. (2003) Disease-speciﬁc accumulation of mutant ubiquitin as
a marker for proteasomal dysfunction in the brain. FASEB J. 17, 2014–2024.
[17] Lindsten, K., de Vrij, F.M., Verhoef, L.G., Fischer, D.F., van Leeuwen, F.W., Hol,
E.M., Masucci, M.G. and Dantuma, N.P. (2002) Mutant ubiquitin found inneurodegenerative disorders is a ubiquitin fusion degradation substrate that
blocks proteasomal degradation. J. Cell Biol. 157, 417–427.
[18] Lam, Y.A., Pickart, C.M., Alban, A., Landon, M., Jamieson, C., Ramage, R., Mayer,
R.J. and Layﬁeld, R. (2000) Inhibition of the ubiquitin–proteasome system in
Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 97, 9902–9906.
[19] van Tijn, P., de Vrij, F.M., Schuurman, K.G., Dantuma, N.P., Fischer, D.F., van
Leeuwen, F.W. and Hol, E.M. (2007) Dose-dependent inhibition of proteasome
activity by a mutant ubiquitin associated with neurodegenerative disease. J.
Cell Sci. 120, 1615–1623.
[20] Shabek, N., Herman-Bachinsky, Y. and Ciechanover, A. (2009) Ubiquitin
degradation with its substrate, or as a monomer in a ubiquitination-
independent mode, provides clues to proteasome regulation. Proc. Natl.
Acad. Sci. USA 106, 11907–11912.
[21] Verhoef, L.G., Heinen, C., Selivanova, A., Halff, E.F., Salomons, F.A. and
Dantuma, N.P. (2009) Minimal length requirement for proteasomal
degradation of ubiquitin-dependent substrates. FASEB J. 23, 123–133.
[22] Lin, M.T. and Beal, M.F. (2006) Mitochondrial dysfunction and oxidative stress
in neurodegenerative diseases. Nature 443, 787–795.
[23] Alonso, A. et al. (2002) Inhibition of T cell antigen receptor signaling by VHR-
related MKPX (VHX), a new dual speciﬁcity phosphatase related to VH1
related (VHR). J. Biol. Chem. 277, 5524–5528.
[24] Gietz, R.D. and Schiestl, R.H. (2007) Microtiter plate transformation using the
LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 5–8.
[25] Schagger, H. (2006) Tricine–SDS–PAGE. Nat. Protoc. 1, 16–22.
[26] Dantuma, N.P., Lindsten, K., Glas, R., Jellne, M. and Masucci, M.G. (2000) Short-
lived green ﬂuorescent proteins for quantifying ubiquitin/proteasome-
dependent proteolysis in living cells. Nat. Biotechnol. 18, 538–543.
[27] Shevchenko, A., Wilm, M., Vorm, O. and Mann, M. (1996) Mass spectrometric
sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68,
850–858.
[28] Schutz-Geschwender, A., Zhang, Y., Holt, T., McDermitt, D. and Olive, M.D.
(2004) Quantitative, Two-Color Western Blot Detection with Infrared
Fluorescence. Technical Report, LI-COR Biosciences, Lincoln, NE.
[29] Johnston, S.C., Larsen, C.N., Cook, W.J., Wilkinson, K.D. and Hill, C.P. (1997)
Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 A
resolution. EMBO J. 16, 3787–3796.
[30] Johnston, S.C., Riddle, S.M., Cohen, R.E. and Hill, C.P. (1999) Structural
basis for the speciﬁcity of ubiquitin C-terminal hydrolases. EMBO J. 18,
3877–3887.
